Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Teng Jin, Ong"'
Autor:
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by
Externí odkaz:
https://doaj.org/article/559690e73ee44470a728f1e9dd145ed5
Autor:
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
IntroductionDespite improvements in the treatment of advanced non-small cell lung cancer (NSCLC), certain patient populations remain underrepresented in clinical trials. Many patients have benefited from platinum doublets, including nab-paclitaxel–
Externí odkaz:
https://doaj.org/article/8c9f2c36e1fc44c697da8f6cbb5a7e44
Autor:
Jonathan W. Goldman, David M. Waterhouse, Ben George, Peter J. O'Dwyer, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Karen Kelly
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC).Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative
Externí odkaz:
https://doaj.org/article/36deb3212f774536b9f45353cdf8f360
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Baseline (screening) vs treatment cycle 2 (P=.06; paired t test). For patient 5, baseline data were not available.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd98b63eb49f579d01cbe44a0a85231
https://doi.org/10.1158/1078-0432.22475423
https://doi.org/10.1158/1078-0432.22475423
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Purpose:Assess safety and efficacy of nivolumab plus nab-paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial.Patients and Methods:Fifty chemotherapy-naive patients receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91944ff29f7b99aa8e56f618a1dd6950
https://doi.org/10.1158/1078-0432.c.6529076.v1
https://doi.org/10.1158/1078-0432.c.6529076.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Percentage lymphocyte subset Ki67+. All patient visits are binned by treatment cycle. Data at baseline and treatment cycle 3 were compared using the Wilcoxon signed rank test. All available data are illustrated; however, statistical comparisons were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af451ccc2b3f88d0ca2643cefe85947
https://doi.org/10.1158/1078-0432.22475429
https://doi.org/10.1158/1078-0432.22475429
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
T-Cell Tumor Infiltration in Tissue-Matched Baseline (screening) and On-Treatment Metastatic Tumors (arm B parts 1 and 2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5462aa83ef7e3c2c1c1145183bef1b4
https://doi.org/10.1158/1078-0432.22475426
https://doi.org/10.1158/1078-0432.22475426
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Investigator-assessed PFS and OS in patients with PD-L1 expression cutoff of 1% (A, B) or 5% (C, D). HR, hazard ratio; mo, months; OS, overall survival; PD-L1, programmed cell death ligand-1; PFS, progression-free survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46e9db745e67db99e4742619e1ece12c
https://doi.org/10.1158/1078-0432.22475435.v1
https://doi.org/10.1158/1078-0432.22475435.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Patients were enrolled in Arm B Part 1 after the safety oversight committee deemed Arm A Part 1 safe. DRC, data review committee; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; RP2D, recommended Part 2 dose.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898ef1dea38981f86f8ebf1a7d51ab9a
https://doi.org/10.1158/1078-0432.22475438
https://doi.org/10.1158/1078-0432.22475438
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Concentrations of CXCL10 (A) and sIL2Rα (B) at baseline and peak on-treatment values. Investigator-assessed PFS in patients with high or low serum cytokines CXCL10 (C) and sIL2Rα (D). CXCL10, interferon gamma-induced protein 10; mo, months; NE, not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b40b6e000cad2b036744f48c00548a3
https://doi.org/10.1158/1078-0432.22475420.v1
https://doi.org/10.1158/1078-0432.22475420.v1